BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
read more...
Nov 22, 2022
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
read more...
Nov 17, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
read more...
Nov 15, 2022
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
read more...
Nov 10, 2022
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
read more...
Nov 09, 2022
BeiGene Reports Third Quarter 2022 Financial Results
read more...
Nov 04, 2022
BeiGene to Present at Upcoming Investor Conferences
read more...
Nov 03, 2022
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
read more...
Nov 02, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
read more...
Oct 26, 2022
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
read more...
Oct 14, 2022
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
read more...
Oct 12, 2022
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
read more...
Sep 19, 2022
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
read more...
Sep 19, 2022
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
read more...
Sep 10, 2022
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
read more...
Sep 07, 2022
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
read more...
Aug 23, 2022
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
read more...
Aug 15, 2022
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
read more...
Aug 09, 2022
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
read more...
Aug 04, 2022
BeiGene Reports Second Quarter 2022 Financial Results
read more...
